Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Tumor and Organ Dose Estimates from 177 Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Prostate-specific membrane antigen expression in normal and malignant human tissues
1997 · External reference
10.2967/jnumed.115.160382
10.2967/jnumed.115.160382 · External reference
10.1007/s00259-014-2949-6
10.1007/s00259-014-2949-6 · External reference
10.1016/j.juro.2015.12.025
10.1016/j.juro.2015.12.025 · External reference
10.1016/j.juro.2016.02.2969
10.1016/j.juro.2016.02.2969 · External reference
10.1007/s00259-014-2713-y
10.1007/s00259-014-2713-y · External reference
10.1158/1078-0432.ccr-13-0231
10.1158/1078-0432.ccr-13-0231 · External reference
10.1056/nejmoa2107322
10.1056/nejmoa2107322 · External reference
[177Lu]Lu-PSMA-617 (PluvictoTM): The first FDA-approved radiotherapeutical for treatment of prostate cancer
10.3390/ph15101292 · 2022 · External reference
10.2967/jnumed.121.262543
10.2967/jnumed.121.262543 · External reference
10.2967/jnumed.123.266638
10.2967/jnumed.123.266638 · External reference
Salivary gland toxicity of PSMA-targeted radioligand therapy with 177Lu-PSMA and combined 225Ac- and 177Lu-labeled PSMA ligands (TANDEM-PRLT) in advanced prostate cancer: a single-center systematic investigation
10.3390/diagnostics12081926 · 2022 · External reference
Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
10.1186/s40658-024-00636-0 · 2024 · External reference
10.2967/jnumed.124.267830
10.2967/jnumed.124.267830 · External reference
10.2967/jnumed.121.261982
10.2967/jnumed.121.261982 · External reference
10.2967/jnumed.115.159012
10.2967/jnumed.115.159012 · External reference
A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project
10.1186/s40658-021-00397-0 · 2021 · External reference
10.2967/jnumed.121.262245
10.2967/jnumed.121.262245 · External reference
10.2967/jnumed.121.262713
10.2967/jnumed.121.262713 · External reference
10.2967/jnumed.123.265448
10.2967/jnumed.123.265448 · External reference
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
10.3389/fonc.2024.1483953 · 2025 · External reference
10.2967/jnumed.124.267452
10.2967/jnumed.124.267452 · External reference
Tolerance of normal tissue to therapeutic radiation
2026 · External reference
10.2967/jnumed.121.262749
10.2967/jnumed.121.262749 · External reference
A method for tumor dosimetry based on hybrid planar-SPECT/CT images and semiautomatic segmentation
10.1002/mp.13178 · 2018 · External reference
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
10.1186/s40658-018-0210-2 · 2018 · External reference
A comparison of 2D and 3D kidney absorbed dose measures in patients receiving 177Lu-DOTATATE
2018 · External reference
10.1007/s00259-010-1422-4
10.1007/s00259-010-1422-4 · External reference
Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
10.1093/annonc/mdz248.006 · 2019 · External reference
